VitaGen Overview
- Year Founded
-
1990
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
VitaGen General Information
Description
Developer of an artificial liver that would be used until a transplant is performed. The ELAD (Extracorporeal Liver Assist Device) Artificial Liver is a two-chambered hollow-fiber cartridge containing a cultured human liver cell line (C3A).
Contact Information
Corporate Office
- 3344 North Torrey Pines Court
- Suite 100
- San Diego, CA 92037
- United States
Corporate Office
- 3344 North Torrey Pines Court
- Suite 100
- San Diego, CA 92037
- United States
VitaGen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 01-Oct-2003 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series 1) | 19-Nov-2002 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 22-Jun-2001 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B1) | 26-Oct-1999 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 06-Aug-1998 | $3M | $15.5M | Completed | Generating Revenue | |
| 1. Later Stage VC (Series A) | 23-Sep-1996 | $12.5M | $12.5M | Completed | Product Development |
VitaGen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 1 |
VitaGen Patents
VitaGen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20020012654-A1 | For production, expression and recovery of harvestable polypeptides, screening compounds for metabolic activity, studying enteric disease and for use in a bio-artificial liver device | Active | 11-Feb-1998 | ||
| AU-761988-B2 | C3a serum-free clonal cell line and methods of use | Inactive | 11-Feb-1998 | ||
| US-6653105-B2 | For production, expression and recovery of harvestable polypeptides, screening compounds for metabolic activity, studying enteric disease and for use in a bio-artificial liver device | Inactive | 11-Feb-1998 | ||
| AU-2667199-A | C3a serum-free clonal cell line and methods of use | Active | 11-Feb-1998 | ||
| AU-6262098-A | Human regeneration-associated serpin-1 (rasp-1) and methods of use | Inactive | 03-Feb-1997 | C07K14/811 |
VitaGen Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| BD Ventures | Corporate Venture Capital | |||
| Becton, Dickinson and Company | Corporation | |||
| BofA Securities | Investment Bank | |||
| Chase Capital Partners | PE/Buyout | Minority |
VitaGen FAQs
-
When was VitaGen founded?
VitaGen was founded in 1990.
-
Where is VitaGen headquartered?
VitaGen is headquartered in San Diego, CA.
-
What industry is VitaGen in?
VitaGen’s primary industry is Other Devices and Supplies.
-
Is VitaGen a private or public company?
VitaGen is a Private company.
-
What is VitaGen’s current revenue?
The current revenue for VitaGen is .
-
How much funding has VitaGen raised over time?
VitaGen has raised $42.3M.
-
Who are VitaGen’s investors?
Alta Partners, BD Ventures, Becton, Dickinson and Company, BofA Securities, and Chase Capital Partners are 5 of 10 investors who have invested in VitaGen.
-
When was VitaGen acquired?
VitaGen was acquired on 01-Oct-2003.
-
Who acquired VitaGen?
VitaGen was acquired by Vital Therapies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
